Hematology and Oncology

We diagnose and treat a broad range of conditions, including:

• Blood cancers such as leukemia and lymphoma
• Immunodeficiency disorders
• Autoimmune diseases
• Serious infectious diseases
• Other rare or chronic hematologic and oncologic conditions

Our physicians work in close coordination with other specialties, ensuring every child receives holistic, individualized care. We also provide integrated palliative care and symptom management for patients with complex, life-limiting illnesses.

Comprehensive Support for Families

We understand that serious diagnoses affect the whole family. Our team is trained to communicate openly and compassionately with children and caregivers, helping you understand what to expect and how to cope with each stage of the treatment journey.

We work closely with children to ensure they feel safe, heard, and empowered during their care. Our child life specialists and psychosocial teams are available to support your family’s emotional well-being throughout the process.

Why Choose Sidra Medicine?

• Expert pediatric hematologists and oncologists
• Multidisciplinary care tailored to your child’s unique needs
• Advanced diagnostic and treatment facilities
• Integrated support services including pain management and psychosocial care
• Child-friendly environment designed to reduce anxiety and promote healing

New Pediatric Hematopoietic Stem Cell Transplant ward

We are opening Qatar’s first Pediatric Hematopoietic Stem Cell Transplant (HSCT) ward in June. The new HSCT ward is dedicated to treating children with blood disorders, immune system diseases, and genetic conditions.

The HSCT ward is a core part of Sidra Medicine’s HSCT Program, using curative therapies to provide life-saving care and treatment for children with a range of blood diseases and cancers. This includes malignant and non-malignant conditions such as leukemia, lymphoma, thalassemia, sickle cell disease, immune deficiencies, and metabolic disorders. HSCT also known as bone marrow transplant, replaces diseased or damaged bone marrow with healthy stem cells from the patient (autologous) or a donor (allogeneic).

Managed by the Hematology and Oncology Division at Sidra Medicine, the new ward is designed exclusively for pediatric patients under the age of 18. It is divided into two main sections: one section for children undergoing HSCT and the other for patients with complex hematology-oncology diagnoses such as cancer, that require intensive chemotherapy and inpatient care.

With an initial capacity of 20 beds, the new HSCT ward integrates cutting-edge infrastructure, including high-level isolation facilities that meet international infection control standards. It is scheduled to receive patients for autologous transplants in late June of 2025 with preparations underway to care for inpatient children who will undergo allogeneic transplants, at a later stage.